Please note: The information displayed on this page might be outdated.
Dynacure: Dynacure is a clinical-stage drug development company focused on improving the lives of patients with rare and orphan diseases. The Dynacure team leverages its proven track record in rare disease drug development to build a pipeline of novel drugs. Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 for the treatment of Centronuclear Myopathies, with Ionis Pharmaceuticals. Dynacure is also building a complementary research portfolio targeting other orphan disorders. The company maintains its headquarters in Strasbourg, France. Dynacure’s investors are Andera Partners, Bpifrance, IdInvest, Ionis Pharmaceuticals, Kurma Partners and Pontifax.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Central Nervous System, Pain, Rare Disease
Finance
Pre-Revenues
Industry
Biotechnology
Investment Participation
CrossOvers
Listing
Private
Therapeutic Modalities
Gene Therapy
Website:
Profiles:
Address:
Bioparc III, 850, Boulevard Sébastien Brant
Illkirch-Graffenstaden, Alsace F-67400
France

Company Participants at Private Company Showcase NYC 2019

  • David Garrett, CFO
  • Stéphane van Rooijen, MD MBA, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.